Compare IDR & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IDR | CBIO |
|---|---|---|
| Founded | 1996 | 2003 |
| Country | United States | United States |
| Employees | 62 | N/A |
| Industry | Precious Metals | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.0M | 537.5M |
| IPO Year | 2000 | 2013 |
| Metric | IDR | CBIO |
|---|---|---|
| Price | $28.28 | $14.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $26.67 |
| AVG Volume (30 Days) | 165.4K | ★ 386.5K |
| Earning Date | 05-13-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 70.15 | N/A |
| EPS | ★ 0.63 | N/A |
| Revenue | ★ $42,406,253.00 | $18,500.00 |
| Revenue This Year | $25.52 | N/A |
| Revenue Next Year | N/A | $279.20 |
| P/E Ratio | $45.65 | ★ N/A |
| Revenue Growth | ★ 64.59 | N/A |
| 52 Week Low | $26.02 | $8.72 |
| 52 Week High | $54.70 | $27.41 |
| Indicator | IDR | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 40.76 | 35.19 |
| Support Level | $27.01 | $9.95 |
| Resistance Level | $35.52 | $18.53 |
| Average True Range (ATR) | 1.30 | 1.45 |
| MACD | -0.07 | -0.52 |
| Stochastic Oscillator | 17.68 | 13.36 |
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. The Company's primary business is exploring for, developing, and extracting gold, and to a lesser extent, silver, and base metal mineral resources in the greater Coeur d'Alene Mining District of North Idaho. The Company produces gold at the Golden Chest Mine located in the Murray Gold Belt area of the world-class Coeur d'Alene Mining District, north of the prolific Silver Valley.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.